Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adhesion Clear all
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

NCT01998633
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 1Phase 2 Interventional

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

NCT03366142
View directory record Official record
Conditions
LAD1
Interventions
Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 4, 2026, 9:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Composition of Dental Plaque

NCT00001726
View directory record Official record
Conditions
Dental Caries, Dental Plaque, Periodontal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 9:52 AM EDT
Completed No phase listed Observational

Hemoglobin Desaturation in Sickle Cell Disease

NCT03908385
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Not applicable Interventional

Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

NCT01095367
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Seprafilm™
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441
View directory record Official record
Conditions
Vitreomacular Adhesion Including Macular Hole
Interventions
Ocriplasmin, Sham injection
Drug · Other
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of Cranberry Ingestion on Bacterial Adhesion: An Adjunct Study

NCT00506025
View directory record Official record
Conditions
Asymptomatic Bacteriuria
Interventions
Cranberry Juice, De-Activated Cranberry juice
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

NCT01849744
View directory record Official record
Conditions
Non Hematologic Cancers, Metastatic Cancer
Interventions
VS-4718
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin

NCT01290978
View directory record Official record
Conditions
Healthy
Interventions
ChloraPrep, DuraPrep
Drug
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

NCT04319926
View directory record Official record
Conditions
Healthy
Interventions
lidocaine topical system 1.8%, lidocaine patch 5%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

NCT00650442
View directory record Official record
Conditions
Healthy
Interventions
Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 66 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Phase 1 Interventional

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

NCT02651727
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
St Louis, Missouri • Gettysburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

NCT01632202
View directory record Official record
Conditions
Intrauterine Adhesions
Interventions
Seprafilm, Sterile Saline Solution
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Not applicable Interventional

Pediatric Adhesion and New Dermal Approach Study

NCT07118124
View directory record Official record
Conditions
Syncope, Pediatric, Congenital Athymia, Congenital Heart Disease, Arrhythmia, Arrhythmia in Children
Interventions
Zio monitor
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boise, Idaho • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 9:52 AM EDT
Not listed Phase 2 Interventional

Pediatric Multicenter Study of REPEL-CV

NCT00116233
View directory record Official record
Conditions
Adhesions
Interventions
REPEL-CV
Device
Lead sponsor
SyntheMed
Industry
Eligibility
1 Day to 1 Year
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Little Silver, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 27, 2005 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Not applicable Interventional Results available

An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery

NCT01002287
View directory record Official record
Conditions
Ulcerative Colitis, Familial Polyposis
Interventions
SprayShield Adhesion Barrier System, Good Surgical Technique Alone
Device · Procedure
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 4, 2026, 9:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With Immune Function Abnormalities

NCT00128973
View directory record Official record
Conditions
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 9:52 AM EDT
Completed No phase listed Observational

Blood Factors and Diabetic Retinopathy

NCT00005761
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 4 Interventional

SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery

NCT00531739
View directory record Official record
Conditions
Adhesions, Colectomy
Interventions
Polylactic Acid Sheet
Other
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Sep 4, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional Results available

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

NCT02004028
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
VS-6063
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 4, 2026, 9:52 AM EDT
Withdrawn No phase listed Observational

Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

NCT01642095
View directory record Official record
Conditions
Childhood Kidney Neoplasm, Clear Cell Renal Cell Carcinoma, Congenital Mesoblastic Nephroma, Rhabdoid Tumor of the Kidney
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 4, 2026, 9:52 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions

NCT05394662
View directory record Official record
Conditions
Intrauterine Adhesion
Interventions
Juveena Hydrogel System, Transcervical Gynecologic Procedures (TCGP)
Device · Procedure
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 4, 2026, 9:52 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 4, 2026, 9:52 AM EDT